Latest News

The listing below shows our latest News Items and is updated regularly.  If you wish to post a news item please select the 'Post News' button on the right.  The displayed news feed starts on 1st August 2016.  Older items can be found here.



Immunocore and MEPC announce significant laboratory expansion at Milton Park in Oxfordshire, UK

Additional space will provide purpose-built research laboratories accommodating around 450 scientists at Immunocore

Read the rest of entry »

Spinning Out Success

OxStem is the largest spin-out company to date to emerge from the University of Oxford's Department of Chemistry.

Read the rest of entry »

Commercializing Cell and Gene Therapies

It takes a commitment to innovation, seamless coordination and the support of an experienced partner to overcome every barrier on the journey from clinical to commercial success.

Read the rest of entry »

Precision for Medicine Expands Its Global Footprint for Oncology Development Services

Leadership in place; Clinical Operations teams growing throughout Europe

BETHESDA, Md., July 6, 2017 /PRNewswire/ -- Precision for Medicine today reported important progress in its global expansion plan. Precision for Medicine, with its oncology research team Precision Oncology, is rapidly expanding its global footprint to better serve clients developing oncology treatments. Investment in executive leadership and operational teams are underway across Europe, providing integrated, full-service clinical trial execution services throughout the continent.

Read the rest of entry »

Devising an efficient roadmap for early stage & start-up companies to maximise value & chances of success

OBN BioTuesday Pennington Manches

Read the rest of entry »

Wickham Laboratories Now Offering Full Suite of Medical Device Biocompatibility and Safety Testing

Medical device testing is one of the most complex services offered in the life sciences sector, both for the diversity of the product tested and for the different level of safety or biocompatibility required prior to approval for use in patients.

Read the rest of entry »

Exscientia enters strategic drug discovery collaboration with GSK

Exscientia, an innovative company at the forefront of Artificial Intelligence (AI)-driven drug discovery, is pleased to announce it has entered into a strategic drug discovery collaboration with GlaxoSmithKline (GSK). During this collaboration, Exscientia will apply its AI enabled platform and combine this with the expertise of GSK, in order to discover novel and selective small molecules for up to 10 disease-related targets, nominated by GSK across multiple therapeutic areas.

Read the rest of entry »

PCI Pharma Services Hay-on-Wye Announces Significant Expansion in Serialization Technology, with Operational Flexible Serialization Suite

Leading outsourcing services provider PCI Pharma Services (PCI) today announced a significant expansion of its market-leading Serialization capability at its Hay-on-Wye site, Wales, UK.  

Read the rest of entry »

Immunocore announces third oncology target selected in discovery collaboration with GlaxoSmithKline

Immunocore will generate a novel ImmTAC® molecule against the selected target which is relevant in multiple cancers.

Read the rest of entry »

AMSBIO announces the launch of DermaChip®

A new high throughput assay technology that allows scientists, for the first time, to reliably measure the genotoxic risk of a whole range of environmental agents (including cleaning agents, household products and industrial chemicals as well as cosmetics) to our skin.

Read the rest of entry »

Search Posts

News Policy

OBN aims to provide sector NEWS that is relevant to our Membership. We filter information from a variety of sources, publish items ourselves and will publish items of News from our Members. Press releases about OBN can be found here.

OBN Noticeboard

This is an impromptu noticeboard to let people know about events, other things that are happening, perhaps lab equipment for sale etc.  Just drop an email to us, team@obn.org.uk, and we will post.